Lakeshore Acquisition I Corp.
LAAA
NASDAQ Capital Market8.69
USD
-0.34
- -
CIK
0001848000
ISIN
KYG535211034
Return %
Stock
S&P500
1Y
-11.78
18.21
3Y
-9.85
63.29
5Y
-9.85
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 555 Shihui Road Shanghai People's Republic of China 201100
- IPO Date
- Jul 23, 2021
- CIK
- 0001848000
- Similar Companies
- Business
- Lakeshore Acquisition I Corp. is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. The company completed a business combination with ProSomnus Holdings, Inc. in December 2022. ProSomnus specializes in manufacturing precision, mass-customized oral appliance therapy devices designed to treat obstructive sleep apnea (OSA), providing an alternative to continuous positive airway pressure (CPAP) therapy. ProSomnus’s core products include patented Precision Oral Appliance Therapy devices, which are the most prescribed for mild-to-moderate OSA treatment in the U.S., with over 150,000 patients treated. The company emphasizes artificial intelligence-driven medical device design, 3D robotic milling, and mass-customized manufacturing processes. Lakeshore Acquisition I Corp. operates primarily in the healthcare and medical device industry, focusing on OSA treatment. The company was formed as a SPAC and is headquartered in San Francisco, California. The most recent major change for Lakeshore Acquisition I Corp. is the approval and closing of the business combination with ProSomnus, which marks its operational focus shift from a blank check company to an active medical device manufacturer and marketer in the U.S. market, expanding its reach and product offerings in the precision oral therapy segment for sleep disorders. This strategic business combination was approved by approximately 92.4% of shareholders and finalized in late 2022, establishing its core operations from that point onward. The company continues to prioritize scaling its business through recruitment of healthcare professionals and expanding adoption of its devices across the United States. Lakeshore Acquisition I Corp. is publicly traded on the Nasdaq under the ticker symbol LAAA. This description covers the company’s main products and services—precision oral appliance devices for OSA—and highlights its recent strategic shift via the ProSomnus merger, moving from a SPAC vehicle to operating medical device company.